Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer.

Abstract

Irinotecan and cisplatin demonstrated promising outcomes in extensive-stage small-cell lung cancer. According to the dosage and schedule of irinotecan, efficacy and toxicity profiles showed subtle differences. This study was designed to evaluate efficacy and toxicity of 3-week schedule of irinotecan/cisplatin in patients with previously untreated extensive-stage small-cell lung cancer. The primary objective was to evaluate response rate and secondary objectives were overall survival and progression-free survival. Patients with previously untreated extensive-stage small-cell lung cancer were enrolled. Irinotecan 65 mg m-2 was administered on days 1 and 8 and cisplatin 60 mg m-2 on day 1. Treatment was repeated every 3 weeks. Seven out of 54 patients (13.0%) had complete response, and partial response was observed in 33 (61.1%). The overall response rate was 74.1% (95% CI; 62.0-82.2%). Stable disease was observed in eight (14.8%) and no progressive disease was observed. After a median follow-up duration of 28.7 months, the median overall survival and progressive-free survival were 13.6 and 6.5 months, respectively. Major grade 3/4 toxicities were neutropenia (50.0%), anorexia (42.6%), diarrhoea (29.6%), fatigue (29.6%) and vomiting (13.0%). There was one treatment-related death owing to pneumonia. Three-week schedule of irinotecan/cisplatin showed effective antitumour activity and moderate toxicities in patients with previously untreated extensive-stage small-cell lung cancer.

• Authors: Y S Hong, H R Lee, S Park, S C Lee, I G Hwang, B-B Park, J Lee, J S Ahn, M-J Ahn, H Y Lim, K Park
• Journal: British journal of cancer (Br J Cancer) Vol. 95 Issue 12 Pg. 1648-52 (Dec 18 2006) ISSN: 0007-0920 [Print] England
• PMID: 17133266 (Publication Type: Clinical Trial, Phase II, Journal Article)

Chemical References

• Irinotecan
• Cisplatin
• Camptothecin

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bone Neoplasms (drug therapy, secondary)
• Camptothecin (administration & dosage, analogs & derivatives)
• Carcinoma, Small Cell (drug therapy, pathology)
• Cisplatin (administration & dosage)
• Drug Administration Schedule
• Female
• Humans
• Irinotecan
• Lung Neoplasms (drug therapy, pathology)
• Lymphatic Metastasis (pathology)
• Male
• Middle Aged
• Neoplasm Staging
• Salvage Therapy
• Survival Rate
• Treatment Outcome